Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 20 de 60
Filtrar
1.
J Korean Med Sci ; 39(31): e223, 2024 Aug 12.
Artículo en Inglés | MEDLINE | ID: mdl-39137810

RESUMEN

BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory cutaneous disorder, that emerges from intricate interplays among genetic predisposition, immune dysregulation, environmental factors, and compromised skin barrier. Understanding the inflammatory pathway in AD is important due to its fundamental role in the pathogenesis of AD. This study aimed to explore the diverse spectrum of proteins linked to the inflammation of AD and the relationship between systemic biomarkers and clinical severity in AD. METHODS: We examined the blood samples from 48 patients with AD and 48 healthy controls (HCs) using the Proximity Extension Assay (Olink). Differentially expressed proteins (DEPs) were identified and Pearson correlation analysis was conducted to determine systemic proteomic biomarkers associated with severity of AD. RESULTS: A total of 29 DEPs were significantly up-regulated and 2 DEPs were significantly down-regulated in AD compared with the HC. The MCP-4, IL-18, MCP-3, TNFRSF9, and IL-17C were the top 5 highest DEPs associated with the severity of AD. CONCLUSION: Our study sheds light on the intricate network of inflammatory proteins in AD and their potential implications for disease severity. Our results indicate that these systemic inflammatory proteins could be valuable for assessing AD severity and enhancing our understanding of the disease's complexity and its potential management strategies.


Asunto(s)
Biomarcadores , Dermatitis Atópica , Proteómica , Índice de Severidad de la Enfermedad , Humanos , Dermatitis Atópica/sangre , Dermatitis Atópica/patología , Dermatitis Atópica/diagnóstico , Biomarcadores/sangre , Biomarcadores/metabolismo , Femenino , Masculino , Adulto , Estudios de Casos y Controles , Adulto Joven , Inflamación/metabolismo , Adolescente , Persona de Mediana Edad
2.
Int J Mol Sci ; 25(10)2024 May 10.
Artículo en Inglés | MEDLINE | ID: mdl-38791249

RESUMEN

Atopic dermatitis (AD) is a chronic inflammatory skin disorder influenced by genetic predisposition, environmental factors, immune dysregulation, and skin barrier dysfunction. The skin microbiome and metabolome play crucial roles in modulating the skin's immune environment and integrity. However, their specific contributions to AD remain unclear. We aimed to investigate the distinct skin microbial communities and skin metabolic compounds in AD patients compared to healthy controls (HCs). Seven patients with AD patients and seven HCs were enrolled, from whom skin samples were obtained for examination. The study involved 16S rRNA metagenomic sequencing and bioinformatics analysis as well as the use of gas chromatography time-of-flight mass spectrometry (GC-TOF-MS) to detect metabolites associated with AD in the skin. We observed significant differences in microbial diversity between lesional and non-lesional skin of AD patients and HCs. Staphylococcus overgrowth was prominent in AD lesions, while Cutibacterium levels were decreased. Metabolomic analysis revealed elevated levels of several metabolites, including hypoxanthine and glycerol-3-phosphate in AD lesions, indicating perturbations in purine metabolism and energy production pathways. Moreover, we found a positive correlation between hypoxanthine and glycerol-3-phosphate and clinical severity of AD and Staphylococcus overgrowth. These findings suggest potential biomarkers for monitoring AD severity. Further research is needed to elucidate the causal relationships between microbial dysbiosis, metabolic alterations, and AD progression, paving the way for targeted therapeutic interventions.


Asunto(s)
Dermatitis Atópica , Metaboloma , Microbiota , Piel , Dermatitis Atópica/microbiología , Dermatitis Atópica/metabolismo , Humanos , Piel/microbiología , Piel/metabolismo , Femenino , Masculino , Adulto , ARN Ribosómico 16S/genética , Metabolómica/métodos , Adulto Joven , Persona de Mediana Edad , Estudios de Casos y Controles
3.
Acta Derm Venereol ; 103: adv18392, 2023 Dec 11.
Artículo en Inglés | MEDLINE | ID: mdl-38078688

RESUMEN

Metformin is a widely used drug for treatment of diabetes mellitus, due to its safety and efficacy. In addition to its role as an antidiabetic drug, numerous beneficial effects of metformin have enabled its use in various diseases. Considering the anti-androgenic, anti-angiogenic, anti-fibrotic and antioxidant properties of metformin, it may have the potential to improve chronic inflammatory skin diseases. However, further evidence is needed to confirm the efficacy of metformin in dermatological conditions, This review focuses on exploring the therapeutic targets of metformin in acne vulgaris, hidradenitis suppurativa and rosacea, by studying their pathogeneses.


Asunto(s)
Acné Vulgar , Hidradenitis Supurativa , Metformina , Rosácea , Humanos , Hidradenitis Supurativa/diagnóstico , Hidradenitis Supurativa/tratamiento farmacológico , Metformina/uso terapéutico , Metformina/farmacología , Acné Vulgar/diagnóstico , Acné Vulgar/tratamiento farmacológico , Rosácea/diagnóstico , Rosácea/tratamiento farmacológico , Piel
4.
Acta Derm Venereol ; 103: adv4557, 2023 Apr 27.
Artículo en Inglés | MEDLINE | ID: mdl-37186168

RESUMEN

Atopic dermatitis (AD) is a chronic inflammatory skin disorder with bimodal incidence peaks in early childhood and middle-aged and older adults. Few studies have focused on the risk of dementia in AD. The aims of this study were to analyse the incidence, and risk factors for dementia in patients with AD. This nationwide population-based retrospective cohort study enrolled 38,391 adults ≥ 40 years of age with AD and 2,643,602 controls without AD from the Korean National Health Insurance System (NHIS) database from 2009 to 2016. The cumulative incidence probability of all-cause dementia, Alzheimer's disease, or vascular dementia at 8 years was 50, 39, and 7 per 1,000 person-years in patients with AD, respectively. The adjusted risks of all-cause dementia (hazard ratio (HR), 1.072; 95% confidence interval (95% CI) 1.026-1.120), and Alzheimer's disease (HR 1.051; 95% CI 1.000-1.104) were increased in patients with AD. The effect of AD on the development of all-cause dementia and Alzheimer's dementia varied according to age and diabetes mellitus (all p for interaction, < 0.05). The risks of all-cause dementia and Alzheimer's disease were increased in patients with AD. Management of modifiable risk factors is important for preventing dementia in patients with AD.


Asunto(s)
Enfermedad de Alzheimer , Dermatitis Atópica , Persona de Mediana Edad , Humanos , Preescolar , Anciano , Enfermedad de Alzheimer/diagnóstico , Enfermedad de Alzheimer/epidemiología , Enfermedad de Alzheimer/etiología , Estudios Retrospectivos , Estudios de Cohortes , Dermatitis Atópica/diagnóstico , Dermatitis Atópica/epidemiología , Dermatitis Atópica/complicaciones , Factores de Riesgo , Incidencia
5.
Acta Derm Venereol ; 103: adv00869, 2023 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-36789757

RESUMEN

Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways. Chronic itch is understood to be processed by the latter and is difficult to treat with traditional pruritus therapies. The Janus kinase and signal transducer and activator of transcription pathway is a signalling mechanism that regulates gene expression through various cytokines. Janus kinase inhibitors, which have been tested and used for several autoimmune diseases, have also been shown to be effective for itch through clinical trials and case reports. Janus kinase inhibitors could be a good choice for pruritus in atopic dermatitis, psoriasis, and other diseases, such as prurigo nodularis and lichen planus, with rapid itch relief compared with conventional treatments. The most common adverse effects reported include nasopharyngitis, acne, and elevated blood creatine phosphokinase levels. Janus kinase inhibitors are currently prescribed with warnings about a potential increase in malignancies and cardiovascular diseases and usage in people of older ages. This review aims to provide knowledge about itch and the Janus kinase and signal transducer and activator of transcription pathway and to analyse the current evidence for itch relief by Janus kinase inhibitors.


Asunto(s)
Dermatitis Atópica , Inhibidores de las Cinasas Janus , Prurito , Enfermedades de la Piel , Humanos , Dermatitis Atópica/tratamiento farmacológico , Inhibidores de las Cinasas Janus/uso terapéutico , Quinasas Janus , Prurito/tratamiento farmacológico , Enfermedades de la Piel/tratamiento farmacológico
6.
J Cutan Med Surg ; 27(6): 601-607, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-37587799

RESUMEN

BACKGROUND: Rosacea is a chronic inflammatory disorder that can adversely affect the patient's quality of life (QOL). However, few studies have examined the association between the psychological burden and willingness to pay (WTP) with rosacea features and severity. OBJECTIVES: The study aimed to determine the overall psychological burden and WTP among Korean rosacea patients and identify factors that may contribute, such as patient demographics, clinical features, and rosacea severity. METHODS: This prospective cross-sectional study recruited Koreans with rosacea. All were asked to complete a questionnaire on their demographics, rosacea-related symptoms, self-rated severity, dermatology life quality index (DLQI), and WTP. The clinical features were assessed by a board-certified dermatologist. The investigator's global assessment and global flushing severity score (GFSS) were used to determine the clinical severity of rosacea. Multiple regression analysis was conducted to identify factors contributing to the psychological burden and WTP. RESULTS: Out of 201 rosacea patients, 147 (73.1%) were female, and 54 (26.9%) males, with a median age of 50.1 years. Their median DLQI score was 8 (interquartile range [IQR]): 4.0-13.0). The median WTP per month for the control of rosacea was $100, with relative WTP (WTP/household income per month x 100) being 3.3%. According to the multiple regression model, phymatous change (ß = .153, p = .030), DLQI score (ß = .152, P = .045), and GFSS (ß = .154, P = .041) contributed most to the WTP. CONCLUSION: Rosacea patients experience substantial psychological and economic burdens. More vigorous treatment should be performed for those with phyma and severe flushing whose QOL is most severely affected.


Asunto(s)
Calidad de Vida , Rosácea , Masculino , Humanos , Femenino , Persona de Mediana Edad , Calidad de Vida/psicología , Estudios Transversales , Estudios Prospectivos , Encuestas y Cuestionarios , República de Corea
7.
Int J Mol Sci ; 23(3)2022 Feb 05.
Artículo en Inglés | MEDLINE | ID: mdl-35163734

RESUMEN

Skin cancer is the most common type of cancer in the US with an increasing prevalence worldwide. While ultraviolet (UV) radiation is a well-known risk factor, there is emerging evidence that the microbiota may also contribute. In recent years, the human microbiota has become a topic of great interest, and its association with inflammatory skin diseases (i.e., atopic dermatitis, acne, rosacea) has been explored. Little is known of the role of microbiota in skin cancer, but with the recognized link between microbial dysbiosis and inflammation, and knowledge that microbiota modulates the effect of UV-induced immunosuppression, theories connecting the two have surfaced. In this paper, we provide a comprehensive review of the key literature on human microbiota, especially the skin microbiota, and skin cancer (i.e., non-melanoma skin cancer, melanoma, cutaneous T cell lymphoma). Also, mechanistic perspectives as to how our microbiota influence skin cancer development and treatment are offered.


Asunto(s)
Dermatitis Atópica , Microbiota , Neoplasias Cutáneas , Disbiosis/complicaciones , Humanos , Piel , Neoplasias Cutáneas/etiología
8.
Exp Dermatol ; 30(3): 396-401, 2021 03.
Artículo en Inglés | MEDLINE | ID: mdl-33141431

RESUMEN

The incidence of Riehl's melanosis (RM) is most common in the fifth or sixth decade of life with a female preponderance. As the skin is regarded a non-reproductive organ on which sex steroid hormones act, a possible relationship between the pathogenesis of RM and sex steroid hormone receptors can be inferred. This study intended to evaluate the expression profile of oestrogen receptor (ER)ß and progesterone receptor (PR) in RM. Twelve lesional and perilesional normal-appearing skin samples of RM patients and the skin of 12 healthy controls were retrieved for the analysis. Real-time PCR analysis and immunohistochemical studies were conducted for ERß and PR, respectively. The lesional and perilesional normal-appearing skin of 12 patients with RM and the skin of 12 healthy controls were retrieved for the analysis. Interestingly, the dermal ERß immunostaining intensity was increased more in lesional skin than in perilesional skin. When compared to healthy controls, increased expression of ERß and PR mRNAs was observed in the lesional skin of patients with RM. Of note, epidermal and dermal ERß and dermal PR expressions showed increased staining intensities in the lesional skin of RM patients compared with healthy controls. The altered expression of ERß and PR in RM supports the possible role of these hormone receptors in the pathogenesis of RM.


Asunto(s)
Receptor beta de Estrógeno/metabolismo , Melanosis/metabolismo , Receptores de Progesterona/metabolismo , Estudios de Casos y Controles , Dermis/metabolismo , Epidermis/metabolismo , Receptor beta de Estrógeno/genética , Femenino , Expresión Génica , Humanos , Melanosis/patología , Comunicación Paracrina , ARN Mensajero/metabolismo , Receptores de Progesterona/genética
9.
Int J Mol Sci ; 21(5)2020 Mar 02.
Artículo en Inglés | MEDLINE | ID: mdl-32121626

RESUMEN

Riehl's melanosis is a hyperpigmentary disorder that occurs predominantly on the face and neck. To date, the pathogenesis of Riehl's melanosis with regards to the melanogenic properties and paracrine melanogenic molecules has not well been studied. This study was aimed to provide a novel perspective on the pathogenesis of Riehl's melanosis by identifying the relevant paracrine melanogenic molecules in Riehl's melanosis. Skin biopsies were performed on lesional and normal-appearing perilesional skin of 12 patients with Riehl's melanosis and 12 age- and sex-matched healthy controls. Histopathological and immunohistochemical staining for paracrine melanogenic molecules was analyzed. The major histopathological findings of Riehl's melanosis were basal hyperpigmentation, melanocyte proliferation, interface change, dermal pigmentary incontinence, vascular proliferation, and dermal inflammation. Dermal expression intensities of stem cell factor (SCF) and c-kit were increased in the lesional skin of Riehl's melanosis. In addition, increased expression of epidermal and dermal ET-1 was also observed in the lesional skin of Riehl's melanosis. Increased tissue expressions of SCF, c-kit, and ET-1 in Riehl's melanosis support the role of these paracrine melanogenic molecules in the pathogenesis of Riehl's melanosis. The findings from this study might present useful information on the pathogenetic mechanism of Riehl's melanosis.


Asunto(s)
Perfilación de la Expresión Génica , Regulación de la Expresión Génica , Melaninas/metabolismo , Melanosis/genética , Comunicación Paracrina , Antígenos CD/metabolismo , Antígenos de Diferenciación Mielomonocítica/metabolismo , Estudios de Casos y Controles , Endotelina-1/metabolismo , Factor XIIIa/metabolismo , Femenino , Humanos , Melanocitos/metabolismo , Melanocitos/patología , Melanosis/patología , Persona de Mediana Edad , Proteínas Proto-Oncogénicas c-kit/metabolismo , Piel/patología , Factor de Células Madre/metabolismo
10.
Int J Mol Sci ; 21(19)2020 Sep 24.
Artículo en Inglés | MEDLINE | ID: mdl-32987907

RESUMEN

Psoriasis and psoriatic arthritis (PsA) have been recently considered as chronic systemic inflammatory disorders. Over the past decades, enormous evidence indicates that patients with psoriasis and PsA have a higher risk of developing various comorbidities including cardiovascular disease, metabolic disease, cancers, infections, autoimmune disease, and psychiatric diseases. However, reported risks of some comorbidities in those with psoriasis and PsA are somewhat different according to the research design. Moreover, pathomechanisms underlying comorbidities of those with psoriasis and PsA remain poorly elucidated. The purpose of this review is to provide the most updated comprehensive view of the risk of systemic comorbidities in those with psoriasis and PsA. Molecular mechanisms associated with the development of various comorbidities in those with psoriasis and PsA are also reviewed based on recent laboratory and clinical investigations. Identifying the risk of systemic comorbidities and its associated pathomechanisms in those with psoriasis and PsA could provide a sufficient basis to use a multi-disciplinary approach for treating patients with psoriasis and PsA.


Asunto(s)
Artritis Psoriásica/epidemiología , Enfermedades Autoinmunes/epidemiología , Enfermedades Cardiovasculares/epidemiología , Infecciones/epidemiología , Enfermedades Metabólicas/epidemiología , Neoplasias/epidemiología , Comorbilidad , Humanos , Factores de Riesgo
11.
Int J Mol Sci ; 21(22)2020 Nov 10.
Artículo en Inglés | MEDLINE | ID: mdl-33182618

RESUMEN

Rosacea is a common chronic cutaneous inflammatory disorder. Recently, patients with rosacea were identified as having a higher risk of developing various comorbidities such as cardiovascular disease, psychiatric disorders, neurologic disorders, and gastrointestinal disorders. However, the risks of some comorbidities in patients with rosacea are somewhat contradictory, depending upon the study design. Moreover, pathomechanisms associated with the comorbidities of patients with rosacea remain poorly elucidated. The purpose of this review was to provide the most up-to-date evidence on the risks of neuropsychiatric and gastrointestinal comorbidities in patients with rosacea. Moreover, the molecular pathomechanisms associated with neuropsychiatric and gastrointestinal comorbidities in patients with rosacea were evaluated based on recent studies. This review was also intended to focus more on the role of the gut-brain-skin axis in the association of neuropsychiatric and gastrointestinal comorbidities in rosacea.


Asunto(s)
Enfermedades Gastrointestinales/complicaciones , Enfermedades del Sistema Nervioso/complicaciones , Rosácea/complicaciones , Encéfalo/fisiopatología , Comorbilidad , Enfermedades Gastrointestinales/epidemiología , Microbioma Gastrointestinal/fisiología , Tracto Gastrointestinal/fisiopatología , Humanos , Incidencia , Modelos Biológicos , Enfermedades del Sistema Nervioso/epidemiología , Factores de Riesgo , Rosácea/epidemiología , Piel/microbiología , Piel/fisiopatología
12.
Int J Mol Sci ; 21(17)2020 Aug 24.
Artículo en Inglés | MEDLINE | ID: mdl-32846909

RESUMEN

Air pollution reportedly contributes to the development and exacerbation of atopic dermatitis (AD). However, the exact mechanism underlying this remains unclear. To examine the relationship between air pollution and AD, a clinical, histological, and genetic analysis was performed on particulate matter (PM)-exposed mice. Five-week-old BALB/c mice were randomly divided into four groups (control group, ovalbumin (OVA) group, PM group, OVA + PM group; n = 6) and treated with OVA or PM10, alone or together. Cutaneous exposure to OVA and PM10 alone resulted in a significant increase in skin severity scores, trans-epidermal water loss (TEWL) and epidermal thickness compared to the control group at Week 6. The findings were further accentuated in the OVA + PM group showing statistical significance over the OVA group. A total of 635, 501, and 2149 genes were found to be differentially expressed following OVA, PM10, and OVA + PM10 exposure, respectively. Strongly upregulated genes included RNASE2A, S100A9, SPRR2D, THRSP, SPRR2A1 (OVA vs. control), SPRR2D, S100A9, STFA3, CHIL1, DBP, IL1B (PM vs. control) and S100A9, SPRR2D, SPRR2B, S100A8, SPRR2A3 (OVA + PM vs. control). In comparing the groups OVA + PM with OVA, 818 genes were differentially expressed with S100A9, SPRR2B, SAA3, S100A8, SPRR2D being the most highly upregulated in the OVA + PM group. Taken together, our study demonstrates that PM10 exposure induces/aggravates skin inflammation via the differential expression of genes controlling skin barrier integrity and immune response. We provide evidence on the importance of public awareness in PM-associated skin inflammation. Vigilant attention should be paid to all individuals, especially to those with AD.


Asunto(s)
Contaminación del Aire/efectos adversos , Dermatitis Atópica/patología , Material Particulado/toxicidad , Piel/efectos de los fármacos , Animales , Dermatitis Atópica/genética , Dermatitis Atópica/inmunología , Dermatitis Atópica/metabolismo , Modelos Animales de Enfermedad , Exposición a Riesgos Ambientales/efectos adversos , Exposición a Riesgos Ambientales/análisis , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Ratones , Ratones Endogámicos BALB C , Tamaño de la Partícula , Factores de Riesgo , Piel/metabolismo , Piel/patología
13.
J Am Acad Dermatol ; 78(3): 471-478.e4, 2018 03.
Artículo en Inglés | MEDLINE | ID: mdl-29107338

RESUMEN

BACKGROUND: Multiple myeloma (MM) is a plasma cell dyscrasia characterized by the presence of a clonal proliferation of tumor cells. Cutaneous involvement of MM is very rare and remains poorly understood. OBJECTIVE: The aim of this study was to examine the clinical and histopathologic characteristics of cutaneous involvement in MM and identify factors associated with overall survival of MM with cutaneous involvement. METHODS: The medical records of 1228 patients with MM were retrieved and analyzed. Of those patients, 14 with cutaneous involvement of MM (1.14%) were further evaluated for their clinical and histopathologic findings. RESULTS: Patients with cutaneous involvement showed significantly reduced overall survival compared with those without cutaneous involvement (median, 28 vs. 57 months; hazard ratio, 1.929; 95% confidence interval, 1.030-3.613). In subgroup analyses of patients with MM with cutaneous involvement, erythematous nodules (P = .004), multiple cutaneous lesions (P = .002), and absence of a grenz zone (P = .004) were clinicopathologic features associated with reduced overall survival after Bonferroni correction. LIMITATIONS: The retrospective design and the small sample size are the limitations. CONCLUSION: Cutaneous involvement accounted for about 1.14% of patients with MM and was associated with reduced overall survival.


Asunto(s)
Cadenas Pesadas de Inmunoglobulina/metabolismo , Cadenas kappa de Inmunoglobulina/metabolismo , Cadenas lambda de Inmunoglobulina/metabolismo , Mieloma Múltiple/patología , Neoplasias Cutáneas/metabolismo , Neoplasias Cutáneas/secundario , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mieloma Múltiple/diagnóstico , Mieloma Múltiple/terapia , Prevalencia , Modelos de Riesgos Proporcionales , República de Corea , Estudios Retrospectivos , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/terapia , Tasa de Supervivencia
15.
Exp Dermatol ; 26(11): 1012-1017, 2017 11.
Artículo en Inglés | MEDLINE | ID: mdl-28370377

RESUMEN

Actinic keratosis (AK) is the most common cutaneous premalignant neoplasm precursor of malignant skin tumors. The aberrant apoptotic pathway is thought to be associated with pathogenesis of AK. Ingenol mebutate has been shown to be effective and safe for treatment of AK. However, the effect of ingenol mebutate on apoptosis-related molecules using human skin samples has not been studied well. Erythroid differentiation regulator 1 (Erdr1) was recently reported to play a crucial role in malignant skin cancers like malignant melanoma. The role of Erdr1 in premalignant actinic keratosis (AK) has not been explored. The purpose of this study was to investigate whether the expression of apoptosis-associated molecules such as Erdr1, p53 and bcl-2 was affected by the treatment of ingenol mebutate in AK. Nine patients with AK underwent skin biopsy at baseline and 8 weeks after treatment with ingenol mebutate for immunohistochemical evaluation with Erdr1, p53 and bcl-2. In addition, skin samples from five control subjects were retrieved. Upregulation of Erdr1 and a significant decrease in expression of p53 and bcl-2 were observed after treatment with ingenol mebutate. Ingenol mebutate treatment for AK resulted in the modulation of apoptosis-associated molecules with an increase in the expression of Erdr1 and a decrease in the expression of p53 and bcl-2.


Asunto(s)
Antineoplásicos/farmacología , Diterpenos/farmacología , Queratosis Actínica/metabolismo , Proteínas de la Membrana/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Proteína p53 Supresora de Tumor/metabolismo , Proteínas Supresoras de Tumor/metabolismo , Anciano , Anciano de 80 o más Años , Antineoplásicos/uso terapéutico , Apoptosis , Diterpenos/uso terapéutico , Regulación hacia Abajo , Humanos , Queratinocitos/metabolismo , Queratosis Actínica/tratamiento farmacológico , Estudios Retrospectivos , Regulación hacia Arriba
16.
Exp Dermatol ; 26(11): 1143-1145, 2017 11.
Artículo en Inglés | MEDLINE | ID: mdl-28500634

RESUMEN

Brimonidine is a highly selective α2-adrenergic receptor agonist approved by the FDA for the treatment of rosacea. Rosacea is a major clinical disease with vasodilatation and rash on the centre of the face, and that brimonidine as a vasoconstrictor can act as a remedy for rosacea. However, there is no study of how brimonidine has an effect on rosacea-related immune cells or mechanisms in the skin to improve rosacea. In this study, we observed that clinical features of rosacea induced by LL-37 in Balb/c mice were improved after the application of brimonidine gel, and we also showed a marked decrease in the number of inflammatory cells, especially mast cells (MCs) histologically. Furthermore, we confirmed that mRNA levels of MC enzymes increased by LL-37 were reduced by brimonidine gel. To our knowledge, we first found that brimonidine has a mechanism of treating rosacea by reducing the number and mRNA levels of MC-specific enzymes, an important immune cell in the pathogenesis of rosacea.


Asunto(s)
Agonistas de Receptores Adrenérgicos alfa 2/uso terapéutico , Tartrato de Brimonidina/uso terapéutico , Movimiento Celular/efectos de los fármacos , Mastocitos/fisiología , Rosácea/tratamiento farmacológico , Administración Cutánea , Agonistas de Receptores Adrenérgicos alfa 2/administración & dosificación , Animales , Péptidos Catiónicos Antimicrobianos , Tartrato de Brimonidina/administración & dosificación , Modelos Animales de Enfermedad , Inducción Enzimática/efectos de los fármacos , Enzimas/genética , Femenino , Geles , Mastocitos/enzimología , Ratones , ARN Mensajero/metabolismo , Rosácea/inducido químicamente , Rosácea/enzimología , Rosácea/patología , Catelicidinas
17.
Int J Mol Sci ; 18(12)2017 Dec 11.
Artículo en Inglés | MEDLINE | ID: mdl-29232931

RESUMEN

Psoriasis is a complex chronic inflammatory cutaneous disorder. To date, robust molecular mechanisms of psoriasis have been reported. Among diverse aberrant immunopathogenetic mechanisms, the current model emphasizes the role of Th1 and the IL-23/Th17 axis, skin-resident immune cells and major signal transduction pathways involved in psoriasis. The multiple genetic risk loci for psoriasis have been rapidly revealed with the advent of a novel technology. Moreover, identifying epigenetic modifications could bridge the gap between genetic and environmental risk factors in psoriasis. This review will provide a better understanding of the pathogenesis of psoriasis by unraveling the complicated interplay among immunological abnormalities, genetic risk foci, epigenetic modification and environmental factors of psoriasis. With advances in molecular biology, diverse new targets are under investigation to manage psoriasis. The recent advances in treatment modalities for psoriasis based on targeted molecules are also discussed.


Asunto(s)
Interleucina-17/genética , Psoriasis/tratamiento farmacológico , Células TH1/inmunología , Células Th17/inmunología , Productos Biológicos/farmacología , Productos Biológicos/uso terapéutico , Ensayos Clínicos como Asunto , Epigénesis Genética , Predisposición Genética a la Enfermedad , Humanos , Interleucina-17/metabolismo , Psoriasis/genética , Psoriasis/inmunología , Transducción de Señal/efectos de los fármacos , Bibliotecas de Moléculas Pequeñas/farmacología , Bibliotecas de Moléculas Pequeñas/uso terapéutico
18.
Int J Mol Sci ; 18(2)2017 Feb 03.
Artículo en Inglés | MEDLINE | ID: mdl-28165377

RESUMEN

Erythroid differentiation regulator 1 (Erdr1) is known to be involved in the inflammatory process via regulating the immune system in many cutaneous disorders, such as psoriasis and rosacea. However, the role of Erdr1 in various hair loss disorders remains unclear. The aim of this study was to investigate the putative role of Erdr1 in alopecias. Skin samples from 21 patients with hair loss disorders and five control subjects were retrieved, in order to assess their expression levels of Erdr1. Results revealed that expression of Erdr1 was significantly downregulated in the epidermis and hair follicles of patients with hair loss disorders, when compared to that in the control group. In particular, the expression of Erdr1 was significantly decreased in patients with alopecia areata. We propose that Erdr1 downregulation might be involved in the pathogenesis of hair loss, and could be considered as a novel biomarker for hair loss disorders.


Asunto(s)
Alopecia/genética , Proteínas de la Membrana/genética , Proteínas Supresoras de Tumor/genética , Alopecia/diagnóstico , Alopecia/metabolismo , Biomarcadores , Estudios de Casos y Controles , Regulación hacia Abajo , Epidermis/metabolismo , Epidermis/patología , Epitelio/metabolismo , Epitelio/patología , Expresión Génica , Folículo Piloso/metabolismo , Humanos , Inmunohistoquímica , Proteínas de la Membrana/metabolismo , Proteínas Supresoras de Tumor/metabolismo
20.
Int J Mol Sci ; 17(9)2016 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-27649161

RESUMEN

Rosacea is a chronic cutaneous inflammatory disease that affects the facial skin. Clinically, rosacea can be categorized into papulopustular, erythematotelangiectatic, ocular, and phymatous rosacea. However, the phenotypic presentations of rosacea are more heterogeneous. Although the pathophysiology of rosacea remains to be elucidated, immunologic alterations and neurovascular dysregulation are thought to have important roles in initiating and strengthening the clinical manifestations of rosacea. In this article, we present the possible molecular mechanisms of rosacea based on recent laboratory and clinical studies. We describe the genetic predisposition for rosacea along with its associated diseases, triggering factors, and suggested management options in detail based on the underlying molecular biology. Understanding the molecular pathomechanisms of rosacea will likely aid toward better comprehending its complex pathogenesis.


Asunto(s)
Rosácea/patología , Butirofilinas/genética , Predisposición Genética a la Enfermedad , Glutatión Transferasa/genética , Cadenas alfa de HLA-DR/genética , Humanos , Sistema Inmunológico/metabolismo , Proteína Adaptadora de Señalización NOD2/genética , Rosácea/genética , Rosácea/metabolismo , Piel/parasitología , Piel/efectos de la radiación , Rayos Ultravioleta
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda